Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting
Ryan C. Gimple, … , Sameer Agnihotri, Jeremy N. Rich
Ryan C. Gimple, … , Sameer Agnihotri, Jeremy N. Rich
Published February 16, 2023
Citation Information: JCI Insight. 2023;8(6):e158077. https://doi.org/10.1172/jci.insight.158077.
View: Text | PDF
Research Article Oncology Stem cells

Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting

  • Text
  • PDF
Abstract

Glioblastoma is the most malignant primary brain tumor, the prognosis of which remains dismal even with aggressive surgical, medical, and radiation therapies. Glioblastoma stem cells (GSCs) promote therapeutic resistance and cellular heterogeneity due to their self-renewal properties and capacity for plasticity. To understand the molecular processes essential for maintaining GSCs, we performed an integrative analysis comparing active enhancer landscapes, transcriptional profiles, and functional genomics profiles of GSCs and non-neoplastic neural stem cells (NSCs). We identified sorting nexin 10 (SNX10), an endosomal protein sorting factor, as selectively expressed in GSCs compared with NSCs and essential for GSC survival. Targeting SNX10 impaired GSC viability and proliferation, induced apoptosis, and reduced self-renewal capacity. Mechanistically, GSCs utilized endosomal protein sorting to promote platelet-derived growth factor receptor β (PDGFRβ) proliferative and stem cell signaling pathways through posttranscriptional regulation of the PDGFR tyrosine kinase. Targeting SNX10 expression extended survival of orthotopic xenograft–bearing mice, and high SNX10 expression correlated with poor glioblastoma patient prognosis, suggesting its potential clinical importance. Thus, our study reveals an essential connection between endosomal protein sorting and oncogenic receptor tyrosine kinase signaling and suggests that targeting endosomal sorting may represent a promising therapeutic approach for glioblastoma treatment.

Authors

Ryan C. Gimple, Guoxin Zhang, Shuai Wang, Tengfei Huang, Jina Lee, Suchet Taori, Deguan Lv, Deobrat Dixit, Matthew E. Halbert, Andrew R. Morton, Reilly L. Kidwell, Zhen Dong, Briana C. Prager, Leo J.Y. Kim, Zhixin Qiu, Linjie Zhao, Qi Xie, Qiulian Wu, Sameer Agnihotri, Jeremy N. Rich

×

Figure 4

SNX10 preferentially affects glioblastoma stem cell proliferation and survival.

Options: View larger image (or click on image) Download as PowerPoint
SNX10 preferentially affects glioblastoma stem cell proliferation and su...
(A) SNX10 mRNA expression by qPCR in 3 patient-derived GSCs following transduction with 3 independent nonoverlapping shRNAs targeting SNX10 or a nontargeting control shRNA (shCONT). n = 3. P values were calculated by 1-way ANOVA with Tukey’s multiple-comparison test. ***P < 0.001. (B) Normalized cell viability of 3 patient-derived GSCs following transduction with 3 shRNAs targeting SNX10 compared to shCONT over a 7-day time course. Repeated measures 2-way ANOVA with Dunnett’s multiple test correction was used for statistical analysis. ***P < 0.001 for all shSNX10 versus shCONT comparisons. (C) SNX10 mRNA expression by qPCR in 3 NSCs following transduction with 3 independent nonoverlapping shRNAs targeting SNX10 or shCONT. n = 4. P values were calculated by 1-way ANOVA with Tukey’s multiple-comparison test. *P < 0.05; **P < 0.01; ***P < 0.001. (D) Normalized cell viability of 3 NSCs following transduction with 3 shRNAs targeting SNX10 compared to shCONT over a 7-day time course. Repeated measures 2-way ANOVA with Dunnett’s multiple test correction was used for statistical analysis. **P < 0.01; ***P < 0.001 for shSNX10 versus shCONT comparisons. (E) Relative SNX10 mRNA expression in 3 DGCs following transduction of 2 shRNAs targeting SNX10 compared to shCONT. n = 3. Significance was determined by 1-way ANOVA with Tukey’s multiple-comparison test. (F) Normalized cell viability of 3 DGCs following transduction with 2 shRNAs targeting SNX10 compared to shCONT over a 6-day time course. n = 3. Significance was determined by 2-way ANOVA with Tukey’s multiple-comparison test. ***P < 0.001. (G) Relative SNX10 mRNA expression in nonmalignant brain culture 263 (NM263) or NM290 following transduction of 2 shRNAs targeting SNX10 compared to shCONT. n = 3. Significance was determined by 1-way ANOVA with Tukey’s multiple-comparison test. ***P < 0.001. (H) Normalized cell viability of NM263 or NM290 following transduction with 2 shRNAs targeting SNX10 compared to shCONT over a 6-day time course. n = 3. Significance was determined by 2-way ANOVA with Tukey’s multiple-comparison test. ***P < 0.001 for all shSNX10 versus shCONT comparisons. (I) Normalized cell viability of GSC CW738, GSC CW468, GSC 2012, and GSC 3565 following transduction with 1 of 2 sgRNAs targeting SNX10 compared to a nontargeting sgRNA (sgCONT) over a 6-day time course. n = 3. Significance was determined by 2-way ANOVA with Tukey’s multiple-comparison test. Data are presented as mean ± SD. NS, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts